37413-91-5

37413-91-5 structure

Name: 21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione
Chemical Name: [2-[(8S,10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,12,14,15-hexahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
CAS Number: 37413-91-5
Molecular Formula: C₂₃H₂₆O₄
Molecular Weight: 366.450
Catalog: Signaling Pathways GPCR/G Protein Glucocorticoid Receptor
Create Date: 2018-08-30 11:11:38
Modify Date: 2024-01-08 10:54:30
21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione is an intermediate of delta 9,11 steroids synthesis, for example, Vamorolone (HY-109017). The delta 9,11 steroids are modifications of glucocorticoids and has anti-inflammatory properties. The delta 9,11 steroids are agents for protection against cell damage (lipid peroxidation) and inhibition of neovascularization[1].

Name	[2-[(8S,10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,12,14,15-hexahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
Synonyms	21-(Acetyloxy)pregna-1,4,9(11),16-tetraene-3,20-dione EINECS 253-497-3 16-tetraene-3,20-dione 21-acetate 21-hydroxypregna-1,4,9(11) 21-acetoxy-pregna-1,4,9(11),16-tetraene-3,20-dione 3,20-Dioxopregna-1,4,9(11),16-tetraen-21-yl acetate 21-Acetoxy-pregna-1,4,9(11),16-tetraen-3,20-dion Pregna-1,4,9(11),16-tetraene-3,20-dione, 21-(acetyloxy)- 21-hydroxy-pregna-1,4,9(11),16-tetraene-3,20-dione 21-acetate 2-((8S,10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate 21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione

Description	21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione is an intermediate of delta 9,11 steroids synthesis, for example, Vamorolone (HY-109017). The delta 9,11 steroids are modifications of glucocorticoids and has anti-inflammatory properties. The delta 9,11 steroids are agents for protection against cell damage (lipid peroxidation) and inhibition of neovascularization[1].
Related Catalog	Research Areas >> Inflammation/Immunology Research Areas >> Metabolic Disease Signaling Pathways >> GPCR/G Protein >> Glucocorticoid Receptor
In Vitro	Δ9,11 derivatives are designed and developed to stably incorporate into cell membranes and inhibit lipid peroxidation without glucocorticoid or mineralocorticoid activities, thus avoiding side effects associated with traditional corticosteroids[1]. VBP15 acts as a lead compound due to potent NF-κB inhibition and GR translocation similar to prednisone and dexamethasone, lack of transactivation properties, and good bioavailability[1].
References	[1]. Erica K M Reeves, et al. VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. Bioorg Med Chem

108-75-8

37413-91-5

Literature: Schaub et al. Journal of the American Chemical Society, 1959 , vol. 81, p. 4962,4966

50-24-8

37413-91-5

Literature: Hulcoop, David G.; Shapland, Peter D.P. Steroids, 2013 , vol. 78, # 12-13 p. 1281 - 1287

23460-76-6

37413-91-5

Literature: Am.Cyanamid Co. Patent: US2864834 , 1957 ;